ANCHOR-RA Study

  • Research type

    Research Study

  • Full title

    A Prospective, Multi-national, Cross-sectional Study on a Risk-factor Guided Approach to Interstitial Lung Disease Screening in Patients with Rheumatoid Arthritis at Higher Risk for ILD Using High Resolution Computed Tomography

  • IRAS ID

    304541

  • Contact name

    Paul Emery

  • Contact email

    P.Emery@leeds.ac.uk

  • Sponsor organisation

    Boehringer Ingelheim International GmbH

  • Clinicaltrials.gov Identifier

    NCT05855109

  • Duration of Study in the UK

    1 years, 0 months, 0 days

  • Research summary

    The overall aim of the study is to develop and validate a rheumatoid arthritis
    (RA) - interstitial lung disease (ILD) clinical prediction model (screening tool)
    based on risk factors to guide screening for ILD in patients with RA using high
    resolution computed tomography (HRCT).

    Primary objectives
    1. To identify factors associated with the development of ILD and to
    establish and validate a multivariable clinical prediction model for
    identification of ILD in RA patients.
    2. To establish clinical decision rules on the use of HRCT for screening for
    ILD in RA patients that are associated with a high probability for ILD.
    3. To characterize the prevalence and radiological features of ILD.

    Secondary objectives
    1. To describe the disease characteristics (e.g., age at RA diagnosis,
    duration of RA, forced vital capacity [FVC], diffusing capacity for
    carbon monoxide [DLco]) of RA-ILD patients with and without
    respiratory symptoms (cough and dyspnoea).
    2. To compare the diagnostic accuracy of prediction models in
    asymptomatic and symptomatic populations, respectively.
    3. To compare the diagnostic accuracy of spirometry, DLco, and
    respiratory examination to HRCT findings relevant to RA-ILD.

    Exploratory objectives
    1. To assess the predictive performance of the model established in
    primary analysis that additionally contains research biomarkers (e.g.,
    Mucin 5B [MUC5B] promoter variant). If research biomarkers are
    informative, clinical decision rules are to be established.
    2. To assess the predictive performance of the model established in
    primary analysis using endpoints definitions according to different
    thresholds of ILD extension and various ILD patterns on HRCT.
    3. To characterize the prevalence and radiological features of bronchiectasis.
    4. To characterize the prevalence and radiological features of emphysema.
    5. To compare the diagnostic accuracy of screening lung ultrasound to
    HRCT (sub-study).

  • REC name

    London - Westminster Research Ethics Committee

  • REC reference

    23/LO/0742

  • Date of REC Opinion

    5 Sep 2023

  • REC opinion

    Favourable Opinion